
Pfizer Ends Sangamo Alliance With Gene Remedy for Hemophilia on Cusp of FDA Submitting
Pfizer’s analysis partnership with Sangamo Therapeutics produced a hemophilia A gene remedy that reached FDA discussions a few regulatory submission. That’s so far as the alliance will go. Pfizer is terminating the seven-year-old pact, a transfer that comes earlier than the pharmaceutical large should pay pricey milestone funds for a product with unsure business prospects.
In keeping with Sangamo, Pfizer mentioned the termination displays its resolution to not go ahead with regulatory submissions for the hemophilia A gene remedy, giroctocogene fitelparvovec. The termination was introduced after Monday’s market shut. When the termination takes impact in April, Sangamo will regain all rights to the gene remedy. The Brisbane, California-based biotech mentioned it nonetheless goals to advance this system and can discover all choices, together with in search of a brand new collaboration accomplice to take the remedy by way of regulatory evaluation and commercialization.
Giroctocogene fitelparvovec is a functioning model of the gene that codes for issue VIII, the clotting protein that’s poor in hemophilia A sufferers. The one-time therapy is meant to allow sufferers to provide issue VIII, bringing that protein nearer to regular ranges. Underneath the collaboration settlement signed in 2017, Sangamo was chargeable for Part 1/2 improvement of the gene remedy. Pfizer’s accountability spanned late-stage improvement, regulatory submissions, and commercialization.
This previous summer season, Pfizer reported preliminary Part 3 outcomes displaying the gene remedy led to statistically vital reductions in annualized bleeding charges by way of 15 months. The pharma large mentioned it deliberate to satisfy with regulators. In keeping with Sangamo, Pfizer had mentioned it anticipated U.S. and European regulatory submissions would occur in early 2025. As not too long ago as final month, Pfizer indicated it was discussing the info with regulators.
Hemophilia gene therapies have made it by way of regulatory evaluation. Pfizer did it earlier this yr, profitable FDA approval for Beqvez, a hemophilia B gene remedy that was licensed from Spark Therapeutics. However commercializing dear hemophilia gene therapies has confirmed to be tough. For sufferers who can handle hemophilia with infusions of clotting proteins or power dosing of sure medicine, one-time therapy from gene remedy has been a troublesome promote. Newer hemophilia medicine are coming into the market, giving sufferers much more decisions. Pfizer has one in every of them with Hympavzi, a once-weekly injectable drug permitted by the FDA in October for each hemophilia A and B.
The commercialization challenges going through hemophilia gene therapies are forcing corporations to make arduous decisions. Lackluster gross sales of Roctavian, a BioMarin Pharmaceutical gene remedy for hemophilia A permitted final yr, have led that firm to discover choices together with divestiture of the product. Now Pfizer has determined to not proceed with Sangamo’s hemophilia A gene remedy.
Underneath the gene remedy alliance, Sangamo acquired $70 million up entrance. In keeping with the biotech’s monetary studies, it had acquired $55 million in milestone funds to date. As much as $220 million in further milestone funds remained excellent. Sangamo was relying on the Pfizer funds for its survival.
Collaborations with Novartis and Biogen ended final yr, main Sangamo to implement a company restructuring and layoffs. Sangamo has since inked offers with Genentech and Astellas Pharma, however these agreements include small upfront funds and milestones which may be years away. In its monetary studies, Sangamo mentioned it has explored the potential for submitting for chapter safety. The corporate’s money place as of Sept. 30 was $39.2 million, in line with its report for the third quarter of 2024. Sangamo mentioned it anticipated to have sufficient money to final solely into the primary quarter of 2025.
Sangamo wants money to help its pipeline of neurology genomic medicines, together with a gene remedy for Fabry illness. In October, the FDA confirmed to the corporate that Part 1/2 information could be adequate to help a regulatory submission below the accelerated approval pathway. The corporate deliberate a submission for the second half of 2025.
Within the announcement of the Pfizer termination, Sangamo mentioned it believes it may chart a path ahead for its applications, however the firm acknowledged that further funding is important for advancing every of them, together with the hemophilia A gene remedy. In a ready assertion, Sangamo CEO Sandy Macrae mentioned the corporate was stunned and disillusioned by Pfizer’s resolution to finish the collaboration so near the anticipated regulatory submissions.
“We’re dedicated to exploring the optimum path ahead for this vital therapy, together with in search of the suitable accomplice with the main focus and understanding of the genomic drugs business surroundings to carry this drugs to sufferers,” he mentioned.
Illustration: Kuzma, Getty Pictures